The Ministry of Health and Family Welfare (Govt. of India) on January 18, 2022, has issued the Drugs (Amendment) Rules, 2022 to further amend the Drugs Rules, 1945.
The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.
In Rule 96 Relating To The Manner Of Labelling, The Following Sub-rule Shall Be Inserted:
According to the gazette notification, the new drug amendments rule states that every active pharmaceutical ingredient (API) imported or manufactured in India shall bear a QR (quick response) code on the label and at every packaging level. The QR code must encase essential data that can be read through computer software for efficient tracking and tracing.
Special storage conditions required (if any). This amendment will come into force on the 1st of Jan 2023. You will need to implement a solution before that.
The Stored Data Must Contain the Following Information
- Unique product identification code
- Name of the API
- Brand name (if any)
- Name and address of the manufacturer
- Batch no.
- Batch size
- Date of manufacturing
- Date of expiry or retesting
- Serial shipping container code (SSCC)
- Manufacturing licence no. or import licence no.
Reference:
https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/
Donald Trump’s tariffs of 50% have come into force on most US imports from India. India’s giant generic pharmaceuticals sector and its electronics and petroleum products are exempt from the tariffs. Aluminium, steel and copper remain at 25%, but job-heavy sectors such as textiles, jewellery, seafood and leather are squarely in the line of fire.
The European Chemicals Agency (ECHA) has published the updated proposal to restrict per- and polyfluoroalkyl substances (PFAS) under the EU’s chemicals regulation, REACH. The update has been prepared by the authorities from Denmark, Germany, the Netherlands, Norway and Sweden, who submitted the initial proposal in January 2023.
Most chemicals exported from the 27 member countries of the European Union into the US will be subject to a 15% tariff on top of their selling prices under an agreement signed on July 27 between the US and the European Commission.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.